Clever, Personable, and Unconventional: Affamed Therapeutics’ Risuteganib Luminate Receives Clinical Trial Approval in Mainland China for Intermediate Dry AMD Treatment
Exciting News from AffaMed Therapeutics A Global Leader in Biotechnology SHANGHAI, Sept. 25, 2023 /PRNewswire/ — AffaMed Therapeutics (“AffaMed”), a global biotechnology company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products that address critical unmet medical needs in ophthalmological, neurological and psychiatric disorders, today announced that China’s National Medical Products Administration has…